Palisade Bio Successfully Closes $5 Million Offering
Palisade Bio, Inc. (Nasdaq: PALI), a dedicated clinical-stage biopharmaceutical company, is making strides in its mission to advance healthcare solutions. Recently, they announced the successful closing of an underwritten public offering, which yielded approximately $5 million in gross proceeds before accounting for underwriting commissions and expenses.
Details of the Offering
The offering consisted of two main components: Class A and Class B Units. In total, Palisade Bio offered 158,000 Class A Units, each comprising one share of common stock and a common warrant. In addition, the offering included 3,120,688 Class B Units, consisting of prefunded common stock purchase warrants and common warrants attached. The Class A Units were priced at $1.525, while the Class B Units came in at $1.5249, allowing investors the opportunity to support the company's crucial work.
Understanding the Common Warrants
The common warrants attached to the offering have a set exercise price of $1.40 per share, making them an attractive option for investors looking to support the company’s future. They are exercisable immediately upon issuance and will remain valid for five years, providing flexibility to shareholders excited about Palisade’s pipeline.
Underwriter’s Role and Additional Options
Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for this significant offering. Moreover, they were granted a 45-day option to buy up to 491,803 additional shares or common warrants, ensuring that any over-allotments could be accommodated smoothly at the public offering price, minus underwriting discounts.
Utilization of Raised Funds
The substantial funds raised will primarily support Palisade Bio's planned Phase 1 clinical trial for PALI-2108. Beyond this clinical endeavor, the capital will also bolster their research and development activities and overall working capital. This financial boost positions Palisade Bio for impactful advancements in their therapeutic offerings for patients battling autoimmune and fibrotic diseases.
Revising Previous Warrant Prices
In conjunction with the offering, Palisade Bio has decided to reprice approximately one million previously issued warrants to align with the current exercise price of $1.40 per share. This strategic move strengthens their financial standing and provides a more solid foundation for future endeavors.
Company Focus and Future Directions
Palisade Bio is committed to revolutionizing the treatment landscape for patients suffering from autoimmune, inflammatory, and fibrotic diseases. They aim to achieve this by applying a targeted approach with their novel therapeutics, continuing to innovate and lead within the biopharmaceutical sector.
Connecting with Investors
The company encourages stakeholders and interested parties to engage with them for more insight into their clinical trials and product developments. They emphasize transparent communication and robust support for their investors, underscoring the importance they place on collaboration with their financial partners.
Frequently Asked Questions
What is the purpose of the recent offering by Palisade Bio?
The offering aims to raise funds to support the Phase 1 clinical trial of PALI-2108, along with additional research and development activities.
How will the raised funds be utilized specifically?
Funds will be primarily allocated to clinical trials, preclinical studies, R&D, and enhancing the company’s working capital.
Who managed the offering for Palisade Bio?
Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager for the public offering.
What are the details regarding the warrants associated with the offering?
Common warrants have an exercise price of $1.40 per share, are exercisable from the time of issuance, and have a five-year term.
How can investors access information about the offering?
Investors can find more details in the prospectus filed with the SEC and can reach out to the investor relations team for inquiries.
